Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/199846
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Penack, Olaf | - |
dc.contributor.author | Peczynski, Christophe | - |
dc.contributor.author | Koenecke, Christian | - |
dc.contributor.author | Polge, Emmanuelle | - |
dc.contributor.author | Kuhnl, Andrea | - |
dc.contributor.author | Fegueux, Nathalie | - |
dc.contributor.author | Daskalakis, Michael | - |
dc.contributor.author | Kröger, Nicolaus | - |
dc.contributor.author | Dreger, Peter | - |
dc.contributor.author | Besley, Caroline | - |
dc.contributor.author | Schanz, Urs | - |
dc.contributor.author | Bloor, Adrian | - |
dc.contributor.author | Ganser, Arnold | - |
dc.contributor.author | Forcade, Edouard | - |
dc.contributor.author | López Corral, Lucía | - |
dc.contributor.author | Passweg, Jakob R. | - |
dc.contributor.author | Novak, Urban | - |
dc.contributor.author | Moiseev, Ivan | - |
dc.contributor.author | Schoemans, Hélène | - |
dc.contributor.author | Basak, Grzegorz W. | - |
dc.contributor.author | Chabannon, Christian | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Averbuch, Dina | - |
dc.contributor.author | Glass, Bertram | - |
dc.contributor.author | Cámara, Rafael de la | - |
dc.contributor.author | Peric, Zinaida | - |
dc.date.accessioned | 2023-06-26T10:48:55Z | - |
dc.date.available | 2023-06-26T10:48:55Z | - |
dc.date.issued | 2023-04-18 | - |
dc.identifier.issn | 2051-1426 | - |
dc.identifier.uri | http://hdl.handle.net/2445/199846 | - |
dc.description.abstract | We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) >= grade 3 cytopenia. In the EBMT CAR-T registry, we identified 398 adult patients with large B-cell lymphoma who had been treated with CAR-T-cells with axicel (62%) or tisacel (38%) before August 2021 and had cytopenia status documented for the first 100 days. Most patients had received two or three previous lines of therapy, however, 22.3% had received four or more. Disease status was progressive in 80.4%, stable in 5.0% and partial/complete remission in 14.6%. 25.9% of the patients had received a transplantation before. Median age was 61.4 years (min-max; IQR=18.7-81; (52.9-69.5)).The cumulative incidence of >= grade 3 cytopenia was 9.0% at 30 days (95% CI (6.5 to 12.1)) and 12.1% at 100 days after CAR T-cell infusion (95% CI (9.1 to 15.5)). The median time from CAR-T infusion to cytopenia onset was 16.5 days (min-max; IQR=1-90; (4-29.8)). Grade 3 and grade 4 CTCAE cytopenia occurred in 15.2% and 84.8%, respectively. In 47.6% there was no resolution.Severe cytopenia had no significant impact on overall survival (OS) (HR 1.13 (95% CI 0.74 to 1.73), p=0.57). However, patients with severe cytopenia had a poorer progression-free survival (PFS) (HR 1.54 (95% CI 1.07 to 2.22), p=0.02) and a higher relapse incidence (HR 1.52 (95% CI 1.04 to 2.23), p=0.03). In those patients who developed severe cytopenia during the first 100 days (n=47), OS, PFS, relapse incidence and non-relapse mortality at 12 months after diagnosis of severe cytopenia were 53.6% (95% CI (40.3 to 71.2)), 20% (95% CI (10.4 to 38.6)), 73.5% (95% CI (55.2 to 85.2)) and 6.5% (95% CI (1.7 to 16.2)), respectively.In multivariate analysis of severe cytopenia risk factors, only year of CAR-T infusion (HR=0.61, 95% CI (0.39 to 0.95), p=0.028) and total number of treatment lines before CAR-T infusion (one or two lines vs three or more, HR=0.41, 95% CI (0.21 to 0.83), p=0.013) had a significant positive association with the incidence of cytopenia. Other factors, such as previous transplantation, disease status at time of CAR-T, patient age and patient sex, had no significant association.Our data provide insight on frequency and clinical relevance of severe cytopenia after CAR T-cell therapy in the European real-world setting. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BMJ | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1136/jitc-2022-006406 | - |
dc.relation.ispartof | Journal for ImmunoTherapy of Cancer, 2023, vol. 11, num. 4 | - |
dc.relation.uri | https://doi.org/10.1136/jitc-2022-006406 | - |
dc.rights | cc by-nc (c) Penack, Olaf et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Trasplantament d'òrgans | - |
dc.subject.classification | Trastorns de les plaquetes sanguínies | - |
dc.subject.other | Transplantation of organs | - |
dc.subject.other | Blood platelet disorders | - |
dc.title | Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-06-23T10:30:57Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37072350 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
e006406.full.pdf | 392.22 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License